FSD Pharma Inc
Change company Symbol lookup
Select an option...
HUGE FSD Pharma Inc
DDOG Datadog Inc
CLX Clorox Co
ATTO Atento SA
TOWN TowneBank
CHWY Chewy Inc
O Realty Income Corp
HOOK HOOKIPA Pharma Inc
AI C3.ai Inc
QSG QuantaSing Group Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

FSD Pharma Inc. is a Canada-based biotechnology company. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its compound, ultra-micronized palmitoyl ethylamine (PEA). The Company, through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), is also focused on the research and development of its lead compounds, Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. The Company’s wholly owned subsidiaries include Prismic Pharmaceuticals Inc. and FV Pharma Inc.

Postmarket

Last Trade
Delayed
$1.13
Change Since Close

Change Since Close

Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.

-0.03 (-2.59%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.16
Day's Change
0.09 (8.41%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.20
Day's Low
1.06
Volume
(Heavy Day)
Volume:
123,010

10-day average volume:
71,801
123,010
Historical quotes & splits

Company Profile

FSD Pharma Inc. is a Canada-based biotechnology company. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its compound, ultra-micronized palmitoyl ethylamine (PEA). The Company, through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), is also focused on the research and development of its lead compounds, Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. The Company’s wholly owned subsidiaries include Prismic Pharmaceuticals Inc. and FV Pharma Inc.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
2.00x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

May 2023
Current Month
494.3K
Previous Month
520.8K
Percent of Float
1.53%
Days to Cover
5.8350 Days

Share Information

HUGE is in a share class of common stock
Float
34.1M
Shares Outstanding
39.0M
Institutions Holding Shares
13
% Held by Institutions

% Held by Institutions

Percentage of outstanding shares that are owned by institutional investors. Calculated from current quarterly filing as of today.

2.60%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

3rd Party Research Disclosure